Palisade Bio 的溃疡性结肠炎药物 PALI-2108 在早期试验中显示出前景，没有严重的副作用。 Palisade Bio's ulcerative colitis drug, PALI-2108, shows promise in early trials with no serious side effects.

帕利塞德生物对PALI-2108治疗性结肠炎的早期试验显示,该药物在15mg至450mg的剂量中耐受性良好,没有严重的副作用. Palisade Bio's early trials of PALI-2108 for Ulcerative Colitis show the drug is well-tolerated across doses from 15mg to 450mg, with no serious side effects. 该药物还显示出延迟释放和延长释放的特性。 The drug also demonstrated delayed-release and extended-release properties. Palisade开始测试重复剂量,公司股票上涨10.23%,达到市场前1.94美元。 Palisade has moved on to testing repeat dosing and the company's stock rose by 10.23% to $1.94 pre-market.